Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit

Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, September 29, 2023
Information
Tags: 
Biotechnology, Health Technology, Health, Medical Devices, Central Florida, Fellow, Femoral vein, Atrial fibrillation, Faculty of Medicine, University of Colombo, Associate, AF, AdventHealth, Medical device, Electrophysiology
Geotags: 
CALIFORNIA, OHIO, UNITED STATES, NORTH AMERICA
⚠ partially generated by AI ↴
Organisation: 
PULSE BIOSCIENCES, PULSE BIOSCIENCES, INC., PULSE BIOSCIENCES®
Stock Symbol: 
NASDAQ:PLSE
Summary
Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.
  • “I believe Pulse Biosciences’ nsPFA circumferential catheter system represents a novel and highly differentiated solution for the treatment of atrial fibrillation by electrophysiologists.
  • Consistently performing circumferential ablations of targeted pulmonary veins in a single shot, in approximately 5 seconds with nsPFA, not only represents a significant time advantage, but also a simpler procedure that could lead to improved patient outcomes,” said Dr. Usman Siddiqui, Chief of Electrophysiology at Advent Health, Director of EP at Advent/Nicholson Center, Associate Professor of Medicine University of Central Florida.
  • “I look forward to detailing both the utility of the novel energy modality and its potential impact on the treatment of AF with fellow EPs at the Global EP Summit.”
    During this presentation, Dr. Usman Siddiqui will be discussing Pulse Biosciences’ nsPFA technology and catheter system.


Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a presentation at the Global EP Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.

“I believe Pulse Biosciences’ nsPFA circumferential catheter system represents a novel and highly differentiated solution for the treatment of atrial fibrillation by electrophysiologists. Consistently performing circumferential ablations of targeted pulmonary veins in a single shot, in approximately 5 seconds with nsPFA, not only represents a significant time advantage, but also a simpler procedure that could lead to improved patient outcomes,” said Dr. Usman Siddiqui, Chief of Electrophysiology at Advent Health, Director of EP at Advent/Nicholson Center, Associate Professor of Medicine University of Central Florida. “I look forward to detailing both the utility of the novel energy modality and its potential impact on the treatment of AF with fellow EPs at the Global EP Summit.”

Presentation Details:

Next Generation PFA

Dr. Usman R. Siddiqui

September 29, 2023 from 8:20 am – 8:30 am ET

During this presentation, Dr. Usman Siddiqui will be discussing Pulse Biosciences’ nsPFA technology and catheter system.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Copyright: 
Copyright Business Wire 2023